Table 1 Baseline characteristics of the patients.
Variable | Participating patients N = 40 |
|---|---|
Age (months) (IQR) | 12 (6, 61) |
Age categories, n (%) | |
0–3 months | 5 (13) |
3–12 months | 16 (40) |
1–5 years | 9 (22) |
6–18 years | 10 (25) |
Female, n (%) | 20 (50) |
RACHS-1, n (%) | |
Category 1 | 8 (20%) |
Category 2 | 23(58%) |
Category 3 | 9 (22%) |
pSOFA, score, ± SD | 4 (2,6) |
Average | |
Total days | |
POD 0 | 4 (3, 6) |
POD 1 | 3 (2, 5) |
POD 2 | 3 (2, 6) |
POD 3 | 3 (1, 6) |
Midazolam | |
Average dose by day | |
Total days, μg/kg/day ± SD | 40.5 ± 61.7 |
POD 0, μg/kg/day ± SD | 43.6 ± 55.2 |
POD 1, μg/kg/day ± SD | 31.8 ± 54.8 |
POD 2, μg/kg/day ± SD | 46.5 ± 74.5 |
POD 3, μg/kg/day ± SD | 42.7 ± 68.2 |
Proportion of receiving patients | |
POD 0, n/total patients each day, (%) | 24/40 (60) |
POD 1, n/total patients each day, (%) | 14/40 (35) |
POD 2, n/total patients each day, (%) | 11/29 (37) |
POD 3, n/total patients each day, (%) | 9/25 (36) |
Dexmedetomidine | |
Average dose by day | |
Total days, μg/kg/day ± SD | 0.39 ± 0.32 |
POD 0, μg/kg/day ± SD | 0.50 ± 0.29 |
POD 1, μg/kg/day ± SD | 0.39 ± 0.27 |
POD 2, μg/kg/day ± SD | 0.33 ± 0.31 |
POD 3, μg/kg/day ± SD | 0.13 ± 0.32 |
Proportion of receiving patients | |
POD 0, n/total patients each day, (%) | 38/40(95) |
POD 1, n/total patients each day, (%) | 36/40 (90) |
POD 2, n/total patients each day, (%) | 22/29 (76) |
POD 3, n/total patients each day, (%) | 13/25 (52) |
Fentanyl | |
Average dose by day | |
Total days, μg/kg/day ± SD | 0.48 ± 0.48 |
POD 0, μg/kg/day ± SD | 0.76 ± 0.49 |
POD 1, μg/kg/day ± SD | 0.51 ± 0.48 |
POD 2, μg/kg/day ± SD | 0.34 ± 0.38 |
POD 3, μg/kg/day ± SD | 0.14 ± 0.25 |
Proportion of receiving patients | |
POD 0, n/total patients each day, (%) | 38/40(95) |
POD 1, n/total patients each day, (%) | 36/40 (90) |
POD 2, n/total patients each day, (%) | 20/29 (68) |
POD 3, n/total patients each day, (%) | 15/25 (60) |
